Drug intelligence / Profile preview

AGV06

Development stage: Preclinical
Lead developer: AGV Discovery
Modality: Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

AGV06 is a preclinical-stage therapeutic candidate being developed by AGV Discovery for the treatment of various cancers. The program is characterized by the use of both small molecule and nanobody modalities, although the specific biological target has not been publicly disclosed. AGV Discovery specializes in identifying novel targets within the tumor microenvironment to overcome resistance to current therapies. AGV06 represents one of the earlier-stage assets in the company's oncology pipeline, aiming to provide new therapeutic options for patients with solid tumors.

Beyond the preview

Go deeper on AGV06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGV06.

Explore the full profile